A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active Controlled, Parallel Group, Operationally Seamless Phase II/III Clinical Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Compared to Co-administration of DTwP-HepB-Hib Vaccine and IPV Vaccine in Healthy Infants at 6-, 10-, and 14-week of Age as Primary Series
Latest Information Update: 11 Jul 2025
At a glance
- Drugs DTP-HepB-IPV-Hib vaccine LG Chem (Primary) ; Hib-DTP-hepatitis B vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Hepatitis B; Influenza B virus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors LG Chem
Most Recent Events
- 03 Jul 2025 Status changed from not yet recruiting to recruiting.
- 06 May 2025 New trial record